{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:50:20Z","timestamp":1793638220112,"version":"4.5.1"},"reference-count":136,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2026,6,3]]},"DOI":"10.1080\/14787210.2026.2669588","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:43:21Z","timestamp":1777967001000},"page":"587-602","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Overview of novel cefepime-based \u03b2-lactam\/\u03b2-lactamase inhibitor combinations"],"prefix":"10.1080","volume":"24","author":[{"given":"Luca","family":"Pipit\u00f2","sequence":"first","affiliation":[{"name":"University of Palermo","place":["Palermo, Italy"]},{"name":"AOU Policlinico \u201cP. Giaccone\u201d","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cascio","sequence":"additional","affiliation":[{"name":"University of Palermo","place":["Palermo, Italy"]},{"name":"AOU Policlinico \u201cP. Giaccone\u201d","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"World Health Organization. Antimicrobial resistance [Web]. 2023 [cited 2026 Jan 2]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance"},{"key":"e_1_3_4_4_1","unstructured":"WHO bacterial priority pathogens list 2024: bacterial pathogens of public health importance to guide research development and strategies to prevent and control antimicrobial resistance [web]. 2024 [cited 2026 Jan 2]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240093461"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-020-0429-6"},{"key":"e_1_3_4_6_1","unstructured":"World Health Organization. AWaRe classification of antibiotics for evaluation and monitoring of use [web]. 2023 [cited 2026 Jan 2]. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.04"},{"key":"e_1_3_4_7_1","unstructured":"World Health Organization. 2021 antibacterial agents in clinical and preclinical development: an overview and analysis [web]. 2022 [cited 2026 Jan 2]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240047655"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2024.2427310"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00775-24"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01676-21"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00911"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106738"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106228"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00128-19"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa036"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv166"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv239"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2025.102761"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02073-20"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01614-24"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02529-16"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02184-15"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2024.04.014"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00514-19"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90762-1"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens4030620"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00682"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.09.031"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/apm.70146"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107552"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf364"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf440"},{"issue":"4","key":"e_1_3_4_33_1","first-page":"322","article-title":"In vitro activity of cefepime\/enmetazobactam and cefepime\/zidebactam against OXA-48-producing Klebsiella pneumoniae clinical strains","volume":"48","author":"Bulfoni M","year":"2025","unstructured":"Bulfoni M, Tascini C, Grandesso S, et al. In vitro activity of cefepime\/enmetazobactam and cefepime\/zidebactam against OXA-48-producing Klebsiella pneumoniae clinical strains. New Microbiol. 2025;48(4):322\u2013326.","journal-title":"New Microbiol"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14080777"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00924-24"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01281-22"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02338-20"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00339-23"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa391"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac241"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00236-24"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-023-04697-4"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02161-21"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00039-22"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00078-25"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00787-25"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00498-23"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00857-25"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-023-04732-4"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00877-21"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00072-17"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac233"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw593"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx050"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz294"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01726-20"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01854-22"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115327"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2025.01.006"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115481"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa353"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107550"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab067"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad061"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01432-20"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2025.07.011"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00497-24"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab141"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04925-22"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2024.116561"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107407"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1521"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1570278"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106417"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01238-17"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8010032"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.918868"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-19084-6"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00663-23"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02678-21"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab213"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf045"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00432-19"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad210"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky522"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2016.150"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00755-25"},{"key":"e_1_3_4_88_1","unstructured":"EXBLIFEP 2 g\/0.5 g powder for concentrate for solution for infusion [web]. 2024 [cited 2026 Jan 2]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/exblifep-epar-product-information_en.pdf"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00253-22"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15040463"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00061-25"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf096"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01468-20"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00493-25"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00682-18"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00180-20"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-022-00592-w"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02345-24"},{"key":"e_1_3_4_99_1","unstructured":"Pharmacokinetics of cefepime and AAI101 in subjects with renal insufficiency and healthy subjects [web]. 2022 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03680352"},{"key":"e_1_3_4_100_1","unstructured":"Single dose mass balance study with C14 - labeled AAI101 in healthy male volunteers [web]. 2019 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03775668"},{"key":"e_1_3_4_101_1","unstructured":"Cefepime\/AAI101 Phase 2 study in hospitalized adults with cUTI [web]. 2018 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03680612"},{"key":"e_1_3_4_102_1","unstructured":"A study to investigate pk safety tolerability of cefepime-enmetazobactam in pediatric participants with cUTI [web]. 2024 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05826990"},{"key":"e_1_3_4_103_1","unstructured":"Safety and efficacy study of cefepime-AAI101 in the treatment of complicated urinary tract infections [web]. 2020 Mar 10 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03687255"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.17034"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.22870"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0214"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460913.2025.2468112"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01053-21"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac447"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107304"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14111097"},{"key":"e_1_3_4_112_1","unstructured":"Cefepime-taniborbactam vs meropenem in adults with VABP or ventilated HABP (CERTAIN-2) [web]. 2025 Jun 8 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06168734"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab183"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01118-23"},{"key":"e_1_3_4_115_1","unstructured":"MAD study to evaluate the safety tolerability and pharmacokinetics of intravenous zidebactam in healthy adults [web]. 2025 Sep 30 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02674347"},{"key":"e_1_3_4_116_1","unstructured":"Med study to evaluate the safety tolerability and pharmacokinetics of intravenous WCK 5222 (Zidebactam and cefepime) in healthy volunteers [web]. 2016 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02707107?term=NCT02707107&viewType=Card&rank=1"},{"key":"e_1_3_4_117_1","unstructured":"Evaluate the effect of WCK 5222 on the QT\/QTc interval in healthy volunteers [web]. 2018 Jun 13 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03554304?term=NCT03554304&rank=1"},{"key":"e_1_3_4_118_1","unstructured":"Plasma and intrapulmonary concentrations study of WCK 5222 [web]. 2018 Aug 14 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03630094"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01484-18"},{"key":"e_1_3_4_120_1","unstructured":"Study of cefepime-zidebactam (FEP-ZID) in complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) [web]. 2025 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04979806"},{"key":"e_1_3_4_121_1","unstructured":"A Phase 2 prospective multi-center study to determine the efficacy and safety of cefepime-zidebactam (FEP-ZID) WCK 5222 for the treatment of adult subjects with serious infections caused by carbapenem-resistant Gram-negative bacteria including those with underlying kidney dysfunction precluding the use of colistin\/polymyxin B. 2026."},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2025.07.009"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-023-00606-x"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00500-23"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf129"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-025-05106-8"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf638"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02382-18"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10101179"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00828-17"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02596-17"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-023-03608-8"},{"key":"e_1_3_4_133_1","unstructured":"A Phase I study to assess safety tolerability and pharmacokinetics of OP0595 [web]. 2014 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02134834"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02229-19"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01951-1"},{"key":"e_1_3_4_136_1","unstructured":"A study to investigate the intrapulmonary lung penetration of nacubactam in healthy participants [web]. 2018 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03182504"},{"key":"e_1_3_4_137_1","unstructured":"Efficacy and safety of cefepime\/nacubactam or aztreonam\/nacubactam compared to imipenem\/cilastatin in subjects with complicated urinary tract infections or acute uncomplicated pyelonephritis (integral-1) [web]. 2025 [cited 2026 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05887908"},{"key":"e_1_3_4_138_1","unstructured":"P3 study to assess efficacy and safety of cefepime\/nacubactam and aztreonam\/nacubactam versus best Available therapy for adults with infection due to carbapenem resistant Enterobacterales (integral-2) [web]. 2026 [cited 2026 Mar 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05905055"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2026.2669588","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14787210.2026.2669588","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2026.2669588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:29:29Z","timestamp":1781846969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2026.2669588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":136,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,3]]}},"alternative-id":["10.1080\/14787210.2026.2669588"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2026.2669588","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}